3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells

Neurochemical Research

Volumn 41, Issue 9, 2016, Pages 2173-2178

  Goldstein, David S ^a   Jinsmaa, Yunden ^a   Sullivan, Patti ^a   Holmes, Courtney ^a   Kopin, Irwin J ^a   Sharabi, Yehonatan ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Cysteinyl dopamine; DOPAL; DOPET; Hydroxytyrosol; Monoamine oxidase; Parkinson s disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CLORGYLINE; DOPAMINE; HYDROXYTYROSOL; RASAGILINE; SELEGILINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3,4-DIHYDROXYPHENYLACETALDEHYDE; 3,4-DIHYDROXYPHENYLETHANOL; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR; PHENETHYL ALCOHOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; ENZYME INHIBITION; ENZYME METABOLISM; METABOLITE; NONHUMAN; OXIDATION; PC12 CELL LINE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PC12 CELL LINE (PHEOCHROMOCYTOMA);

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DOPAMINE; DOPAMINE AGENTS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXIDATION-REDUCTION; PARKINSON DISEASE; PC12 CELLS; PHENYLETHYL ALCOHOL; RATS;

EID: 84970023647     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-016-1959-0     Document Type: Article

References (20)

1. Burke WJ (2003) 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson’s disease. Curr Drug Targets CNS Neurol Disord 2:143–148
2. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659–665
3. Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1812:663–673
4. Cavalieri EL, Li KM, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG (2002) Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071–1077
5. De Marco F, Perluigi M, Marcante ML, Coccia R, Foppoli C, Blarzino C, Rosei MA (2002) Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells. Biochem Pharmacol 64:1503–1512
6. Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597–15605
7. Linsenbardt AJ, Wilken GH, Westfall TC, Macarthur H (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30:1030–1035
8. Fornstedt B, Carlsson A (1991) Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30:463–468
9. Montine TJ, Picklo MJ, Amarnath V, Whetsell WO Jr, Graham DG (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148:26–33
10. Spencer JP, Whiteman M, Jenner P, Halliwell B (2002) 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81:122–129
11. Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2016) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells. J Pharmacol Exp Ther 356:484–493
12. Rodriguez-Morato J, Xicota L, Fito M, Farre M, Dierssen M, de la Torre R (2015) Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases. Molecules 20:4655–4680
13. de la Torre R, Covas MI, Pujadas MA, Fito M, Farre M (2006) Is dopamine behind the health benefits of red wine? Eur J Nutr 45:307–310
14. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti E, Storelli C, Visioli F, Distante A, De Caterina R (2003) Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 23:622–629
15. Lopez de las Hazas MC, Rubio L, Kotronoulas A, de la Torre R, Sola R, Motilva MJ (2015) Dose effect on the uptake and accumulation of hydroxytyrosol and its metabolites in target tissues in rats. Mol Nutr Food Res 59:1395–1399
16. Gallardo E, Palma-Valdes R, Espartero JL, Santiago M (2014) In vivo striatal measurement of hydroxytyrosol, and its metabolite (homovanillic alcohol), compared with its derivative nitrohydroxytyrosol. Neurosci Lett 579:173–176
17. Tasset I, Pontes AJ, Hinojosa AJ, de la Torre R, Tunez I (2011) Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington’s disease-like rat model. Nutr Neurosci 14:106–111
18. Laschinski G, Kittner B, Brautigam M (1986) Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivatives. Naunyn Schmiedebergs Arch Pharmacol 332:346–350
19. Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y (2015) Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson’s disease. J Neurochem 133:14–25
20. Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2015) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) in PC12 cells. J Pharmacol Exp Ther 356:484–493